Z
Zentalis Pharmaceuticals, Inc. (ZNTL)
NGM – Real Time Price. Currency in USD
4.28
+0.14 (3.38%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
4.28
+0.14 (3.38%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 6.93 | 6.05 | 10 | |
| Quick ratio | 6.93 | 5.63 | 10 | |
| Debt to Equity | 0.18 | 0.30 | 9.0 | |
| Debt to Assets | 0.14 | 1.04 | 8.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | 67M | N/A | N/A |
| Gross Profit | -1M | -1M | 66M | -739K | -739K |
| Operating Income | -227M | -254M | -187M | -146M | -145M |
| Net Income | -237M | -292M | -166M | -137M | -137M |
| EBITDA | -226M | -253M | -186M | -146M | -144M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 28.86 | 5.5 |
| Next quarter | N/A | -26.43 | 1.0 |
| Current year | N/A | 0.17 | 1.5 |
| Next year | N/A | 15.56 | 5.0 |
| Weighted average score | 3.3 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -31.93 | -35.13 | -14.74 | 3.3 |
| Y/Y | -99.99 | 25.82 | 25.37 | 22.07 | 7.8 |
| 3y average | 632.67 | 12.4 | 22.04 | 6.46 | 8.0 |
| 5y average | 779.2 | -9.32 | 11.38 | -13.45 | 4.8 |
| Weighted average score | 6.0 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Total debt $39.6M significantly exceeds cash reserves ($36.0M), raising financial stability concerns
Total current assets $253.2M exceed Total current liabilities $36.6M, highlighting excellent liquidity
Debt-to-equity ratio (0.2) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$30.9M limits the company's ability to reinvest or pay down debt